Rafferty Asset Management LLC Acquires New Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Rafferty Asset Management LLC acquired a new stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 17,431 shares of the company’s stock, valued at approximately $185,000.

A number of other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in Neumora Therapeutics by 2.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock valued at $851,000 after buying an additional 1,629 shares in the last quarter. SkyOak Wealth LLC grew its stake in Neumora Therapeutics by 33.3% in the 4th quarter. SkyOak Wealth LLC now owns 20,000 shares of the company’s stock valued at $212,000 after buying an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Neumora Therapeutics in the 4th quarter valued at approximately $61,000. Charles Schwab Investment Management Inc. grew its stake in Neumora Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 704,154 shares of the company’s stock valued at $7,464,000 after buying an additional 5,899 shares in the last quarter. Finally, PNC Financial Services Group Inc. purchased a new position in Neumora Therapeutics in the 4th quarter valued at approximately $64,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Stock Performance

NASDAQ NMRA opened at $0.68 on Friday. Neumora Therapeutics, Inc. has a 52-week low of $0.61 and a 52-week high of $17.19. The company has a market capitalization of $109.94 million, a P/E ratio of -0.36 and a beta of 2.96. The company has a fifty day moving average of $0.79 and a 200-day moving average of $3.97.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). As a group, analysts forecast that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NMRA has been the subject of several analyst reports. Bank of America reissued an “underperform” rating and issued a $1.00 price target (down from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Guggenheim downgraded shares of Neumora Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, March 7th. William Blair downgraded shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Finally, HC Wainwright cut their price target on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.